Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

593 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of 153Sm-EDTMP with fixed high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
Dispenzieri A, Wiseman GA, Lacy MQ, Litzow MR, Anderson PM, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata L, Elliott MA, Lust JA, Greipp PR, Rajkumar SV, Fonseca R, Witzig TE, Erlichman C, Sloan JA, Gertz MA. Dispenzieri A, et al. Among authors: ansell sm. Leukemia. 2005 Jan;19(1):118-25. doi: 10.1038/sj.leu.2403575. Leukemia. 2005. PMID: 15526021 Clinical Trial.
A role for IFN-lambda1 in multiple myeloma B cell growth.
Novak AJ, Grote DM, Ziesmer SC, Rajkumar V, Doyle SE, Ansell SM. Novak AJ, et al. Among authors: ansell sm. Leukemia. 2008 Dec;22(12):2240-6. doi: 10.1038/leu.2008.263. Epub 2008 Oct 2. Leukemia. 2008. PMID: 18830264 Free PMC article.
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Porrata LF, Rsitow K, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Colgan JP, Nowakowski GS, Thompson CA, Markovic SN. Porrata LF, et al. Among authors: ansell sm. Leukemia. 2010 Jul;24(7):1343-9. doi: 10.1038/leu.2010.108. Epub 2010 May 20. Leukemia. 2010. PMID: 20485372
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, Porrata LF, Ansell SM, Colgan JP, Jacobsen ED, Ghobrial IM, Habermann TM. Witzig TE, et al. Among authors: ansell sm. Leukemia. 2011 Feb;25(2):341-7. doi: 10.1038/leu.2010.226. Epub 2010 Dec 7. Leukemia. 2011. PMID: 21135857 Free PMC article. Clinical Trial.
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
Nowakowski GS, LaPlant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Klebig RR, Reeder CB, Witzig TE. Nowakowski GS, et al. Among authors: ansell sm. Leukemia. 2011 Dec;25(12):1877-81. doi: 10.1038/leu.2011.165. Epub 2011 Jul 1. Leukemia. 2011. PMID: 21720383 Clinical Trial.
593 results